Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perioperative Nivolumab in Resectable Lung Cancer
Tina Cascone, Mark M. Awad, Jonathan Spicer, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1756-1769
Closed Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1240-1252
Closed Access | Times Cited: 22
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 2
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
Dongsheng Yue, Wenxiang Wang, Hongxu Liu, et al.
The Lancet Respiratory Medicine (2024)
Closed Access | Times Cited: 10
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Next-generation combination approaches for immune checkpoint therapy
Sangeeta Goswami, Kristen E. Pauken, Linghua Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 12, pp. 2186-2199
Closed Access | Times Cited: 9
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 583-583
Open Access | Times Cited: 1
Cytoreductive surgery in diffuse pleural mesothelioma. What have we learnt from MARS2, EORTC-L1205 and other recent studies?
Loı̈c Lang-Lazdunski
European Journal of Surgical Oncology (2025), pp. 109628-109628
Closed Access | Times Cited: 1
Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
K Sugiyama, Anderley Gordon, Sanjay Popat, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104122-104122
Closed Access | Times Cited: 1
CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS
Jianxin Wang, Qi Chen, Qi Shan, et al.
Cancer Letters (2025), pp. 217616-217616
Closed Access | Times Cited: 1
Neoadjuvant or Perioperative Approach in Lung Cancer
Marina Chiara Garassino, Valter Torri
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1816-1818
Closed Access | Times Cited: 7
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 7
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Angela Rina, Debora Maffeo, Francesca Minnai, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2882-2882
Open Access | Times Cited: 5
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Mariano Provencio, Ernest Nadal, Amelia Insa, et al.
The Lancet Oncology (2024)
Open Access | Times Cited: 5
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
Daniele Marinelli, A. Nuccio, Alessandro Di Federico, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 4
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
Claudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Cancer Treatment Reviews (2024) Vol. 131, pp. 102845-102845
Closed Access | Times Cited: 4
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P.L. Saw, Wen‐Zhao Zhong, Rui Fu, et al.
Lung Cancer (2025) Vol. 200, pp. 108076-108076
Open Access
Evidence for a reduction in number of cycles of immune checkpoint inhibitors
Abdul-Hamid Bazarbachi, Nicola Magrini, Zeba Aziz, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 9-11
Closed Access
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M. Awad, Patrick M. Forde, Nicolas Girard, et al.
Journal of Clinical Oncology (2025)
Closed Access
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
William J. Phillips, D. Ross Camidge, Paul Wheatley‐Price
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. 30-33
Closed Access
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
Dipesh Uprety, Anja C. Roden, Solange Peters
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. 34-38
Closed Access
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Yuzhu Chen, Fei Qi, Chao Sun, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
POLE mutation associated with microsatellite instability and high tumor mutational burden confers exquisite sensitivity to immune checkpoint inhibitor therapy in non-small cell lung cancer: a case report and genomic database analysis
Matthew S Lara, Jonathan W. Riess, Guneet Kaleka, et al.
Clinical Lung Cancer (2025)
Closed Access
Page 1 - Next Page

Scroll to top